Literature DB >> 11316643

The relationship between atopic status and IL-10 nasal lavage levels in the acute and persistent inflammatory response to upper respiratory tract infection.

J M Corne1, L Lau, S J Scott, R Davies, S L Johnston, P H Howarth.   

Abstract

We examined the influence of atopy on virus-induced airway inflammation by comparing the nasal response to naturally acquired upper respiratory tract infection in atopic and nonatopic subjects by measurement of cytokine, chemokine, and mediator levels in nasal lavage from 44 adults (23 atopic) taken during the acute and the convalescent phases of the common cold. Nasal aspirates were examined for the presence of upper respiratory viruses by RT-PCR. In atopic and nonatopic subjects there were increased levels of IL-1beta, IL-6, IL-8, TNF-alpha, RANTES, sICAM-1, MPO, ECP, IL-10, and IFN-gamma in nasal lavage during the acute compared with the convalescent phase (p < 0.001). During the acute phase histamine levels were significantly higher in the atopic than in the nonatopic subjects (p < 0.05), whereas IL-10 levels were significantly greater in the nonatopic than in the atopic subjects (p < 0.05). At convalescence levels of IL-1beta, IL-6, sICAM-1, ECP, RANTES and albumin were significantly higher in the atopic group (p < 0.05). An upper respiratory tract virus was found in 27 volunteers (61%) during the acute stage and in two volunteers (4%) at convalescence. We conclude that virus-induced inflammatory changes within the nose are more prolonged in atopic than in nonatopic subjects and that this is associated with reduced IL-10 levels in atopic compared with nonatopic subjects during the acute phase of upper respiratory tract infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11316643     DOI: 10.1164/ajrccm.163.5.9902047

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  8 in total

1.  Allergen-specific CD8(+) T cells and atopic disease.

Authors:  Suranjith L Seneviratne; Louise Jones; Abigail S King; Antony Black; Sheila Powell; Andrew J McMichael; Graham S Ogg
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

2.  Nasal mucosa in natural colds: effects of allergic rhinitis and susceptibility to recurrent sinusitis.

Authors:  O-P Alho; R Karttunen; T J Karttunen
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

Review 3.  Asthma exacerbations. 2: aetiology.

Authors:  A M Singh; W W Busse
Journal:  Thorax       Date:  2006-09       Impact factor: 9.139

4.  Lymphocyte and mast cell counts are increased in the nasal mucosa in symptomatic natural colds.

Authors:  O-P Alho; T J Karttunen; R Karttunen; H Tuokko; M Koskela; M Uhari
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

5.  Reduced nasal IL-10 and enhanced TNFalpha responses during rhinovirus and RSV-induced upper respiratory tract infection in atopic and non-atopic infants.

Authors:  I J van Benten; C M van Drunen; J L M Koevoet; L P Koopman; W C J Hop; A D M E Osterhaus; H J Neijens; W J Fokkens
Journal:  J Med Virol       Date:  2005-02       Impact factor: 2.327

6.  Effects of intranasal TNFalpha on granulocyte recruitment and activity in healthy subjects and patients with allergic rhinitis.

Authors:  Henrik Widegren; Jonas Erjefält; Magnus Korsgren; Morgan Andersson; Lennart Greiff
Journal:  Respir Res       Date:  2008-01-30

7.  Longitudinal analysis of inflammatory biomarkers during acute rhinosinusitis.

Authors:  Timo J Autio; Timo Koskenkorva; Tuomo K Leino; Petri Koivunen; Olli-Pekka Alho
Journal:  Laryngoscope       Date:  2016-10-18       Impact factor: 3.325

8.  Anti-bacterial IgE in the antibody responses of house dust mite allergic children convalescent from asthma exacerbation.

Authors:  B J Hales; A C Martin; L J Pearce; K Rueter; G Zhang; S-K Khoo; C M Hayden; J Bizzintino; P McMinn; G C Geelhoed; W-M Lee; J Goldblatt; I A Laing; P N LeSouëf; W R Thomas
Journal:  Clin Exp Allergy       Date:  2009-04-17       Impact factor: 5.018

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.